FGP
MD icon

Freestone Grove Partners’s Pediatrix Medical MD Stock Holding History

Freestone Grove Partners’s Portfolio MD Stock Details MD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,068
Closed -$408K – 1213
2026
Q1 		$408K Buy
+19,068
New +$397K ﹤0.01% 638
2025
Q2 		– Sell
-10,811
Closed -$157K – 785
2025
Q1 		$157K Buy
+10,811
New +$154K ﹤0.01% 551

Other funds holding MD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Freestone Grove Partners's MD Position: Q2 2026 in Review

Freestone Grove Partners sold out of Pediatrix Medical (MD) in Q2 2026, closing a stake of 19,068 shares — an estimated $408K sold.

Freestone Grove Partners first reported a position in MD in Q1 2025 and held it in 2 quarters. The position peaked at $408K in Q1 2026. 304 funds tracked by Wall St. Rank hold MD as of Q2 2026.

  • Freestone Grove Partners reported no remaining Pediatrix Medical position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 19,068 Pediatrix Medical shares in Q2 2026, an estimated $408K.
  • Freestone Grove Partners first reported a position in Pediatrix Medical in Q1 2025 and held it in 2 quarters.
  • Freestone Grove Partners's Pediatrix Medical position peaked at $408K in Q1 2026.
  • 304 funds tracked by Wall St. Rank held Pediatrix Medical as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.